Abstract: A synergistically heat stable therapeutically active triglyceride and cholesterol controlling oil composition including the usually highly unsaturated Eicosa Pentaenoic Acid (EPA) and Docosa Hexaenoic Acid (DHA). The invention avoids limitations of presently available impure sources of EPA/DHA such as fish oil, algae and the like and provides for a synergistically stable edible oil formulation involving the Eicosa Pentaenoic Acid and Docosa Hexaenoic acid of at least 50% to less than 100% purity in a free of any encapsulated/protected form in combination with synergistically stability contributing oil constituents/ingredients. The invention also provides for benefit applications/uses of the surprising and unexpected heat stability of the beneficial actives EPA and DHA. The invention is therefore directed to serve in possible provision of variety of alternative media including heat stable media for regular consumption of EPA/DHA and provide for maintenance of safe and healthy lifestyle.
Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
Type:
Application
Filed:
December 18, 2009
Publication date:
February 9, 2012
Applicant:
PHENOMENOME DISCOVERIES INC.
Inventors:
M. Amin Khan, Paul L. Wood, Dayan Goodenowe, Rishikesh Mankidy, Pearson Ahiahonu
Abstract: A shaped body suitable for use as acid-releasing body in toilets includes 10-95% of a lactic acid oligomer with an average degree of polymerization between 1.8 and 4. The shaped body provides for the controlled release of lactic acid, which serves to reduce or prevent to the formation of calcium and magnesium deposits in the toilet, contributes to soap scum removal, and has a sanitizing and disinfecting effect. The shaped bodies may be used in-bowl or in-cistern.
Abstract: The invention provides a micronized polymer powder compos Won for the use in personal care and cosmetics, the micronized polymer powder composition comprising at least one thermoplastic polyester based on at least one diol and at least one dicarboxylic acid selected from the group consisting of cyclic and branched aliphatic dicarboxylic acids having 4-12 carbon atoms and aromatic dicarboxylic acids having 8-12 carbon atoms. The present invention provides also a cosmetic composition comprising the at least one micronized polymer powder composition according to the invention. The composition according to the invention provides a high-performed gentle exfoliation property of skin care and cosmetic compositions without creating micro cuts and irritation of the skin surface while still providing the range of desired care properties.
Type:
Application
Filed:
April 15, 2010
Publication date:
February 2, 2012
Applicant:
E. I. DU PONT DE NEMOURS AND COMPANY
Inventors:
Oliver Magnin, Carole Gherardi, Vincent Raspail, Ludovic Granjou
Abstract: Described are antibacterial and anti-mould compositions containing high amounts of C1 to C7 organic acid mono-glycerides and glycerol, their preparation and their use in animal feedstuffs.
Abstract: Biomedical uses of amphiphilic macromolecules include the use of such macromolecules in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromolecule encapsulates for treating diseases including cancer and inflammation, as well as targeted amphiphilic macromolecules and their use in therapy.
Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
Type:
Grant
Filed:
August 15, 2007
Date of Patent:
January 24, 2012
Assignee:
AmDerma Pharmaceuticals, LLC
Inventors:
Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
Abstract: A personal care composition comprising: at least a first phase and a second phase wherein said first phase comprises a) an aqueous structured surfactant phase comprising STnS where n is between about 0 and about 2.5; b) ; c) a structuring system comprising i. optionally, a non-ionic emulsifier; ii. optionally, from about 0.05% to about 5%, by weight of said personal care composition, of an associative polymer; iii. an electrolyte; and said second phase comprises a) a benefit phase comprising from 1% to about 50%, by weight of said personal care composition, of a hydrophobic benefit agent.
Type:
Application
Filed:
June 10, 2011
Publication date:
January 12, 2012
Inventors:
Karl Shiqing WEI, Edward Dewey Smith, III, Shawn Lynn Mansfield, Peter Herbert Koenig, Wei Ji, Yogesh Suradkar, Deepa Bagchi, Sujatha Logou, Stevan David Jones
Abstract: The present invention relates to a bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of the animals, and to animal feed comprising same. More particularly, the present invention relates to a bile salt adjuvant for animals comprising sodium stearoyl-2-lactylate. The adjuvant is used in animal feed to improve fat utilization efficiency in the bodies of livestock when ingested by said livestock, thereby reducing the amount of fat required to be used in animal feed and improving productivity.
Abstract: The present invention is directed to a long wearing, transfer resistant cosmetic composition which is waterproof, comfortable and has a unique creamy texture and feel containing: (a) a reaction product of (i) at least one polyamine and (ii) at least one oil soluble high carbon polar modified polymer; (b) water; (c) at least one volatile solvent capable of solubilizing the polar modified polymer; (d) optionally at least one non-volatile solvent; and (e) optionally, at least one colorant.
Type:
Application
Filed:
December 16, 2009
Publication date:
December 22, 2011
Applicant:
L'OREAL S.A.
Inventors:
Hy Si Bui, Susan Halpern, Mohamed Kanji
Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
Abstract: The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present invention such compounds are also for use in the prevention or treatment of diseases caused or affected by a decreased endogenous level of plasmalogens. A method for the manufacture of a dietary precursor for the use of the present invention is also part of the present disclosure.
Abstract: The present invention is related to: (1) a cosmetic preparation including an emulsifying agent, 1,3-propanediol (PDO), and a PDO difatty acid ester, wherein the fatty acids constituting the PDO difatty acid ester are one or two or more types of fatty acids selected from isostearic acid, n-octanoic acid, and n-decanoic acid, and a method for producing the cosmetic preparation; (2) a composition for cosmetic preparations, which includes the PDO difatty acid ester, a cosmetic preparation including the composition for cosmetic preparations, and a method for producing the cosmetic preparation; and (3) a cleanser for industrial use, which includes a PDO difatty acid ester that has fatty acid residues of n-octanoic acid and n-decanoic acid.
Abstract: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants.
Type:
Application
Filed:
August 24, 2011
Publication date:
December 15, 2011
Inventors:
John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck, Uy Nguyen
Abstract: Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months was 1-2 g/kg/24 hrs. The present invention demonstrates, for the first time, the arrest of clinical deterioration with limited functional recovery in APBD with triheptanoin diet therapy.
Abstract: Medical dietary composition for treating neurodegenerative diseases such as Alzheimer, Parkinson's disease, and more preferably adrenoleukodystrophy comprising a mixture of glyceryl trioleate (GTO), glyceryl trierucate (GTE) and at least one conjugated linoleic acid as active ingredient, in combination with suitable excipients and/or diluents.
Type:
Application
Filed:
June 14, 2011
Publication date:
December 15, 2011
Applicant:
SOFEDUS S.R.L.
Inventors:
Anna PETRONI, Sebastiano BANNI, Marco CAPPA
Abstract: Methods of treating seizure disorders by administration of a therapeutically effective amount of at least one precursor of propionyl-CoA in the absence of a ketogenic diet are provided. The present invention particularly applies to administration of triglyceride oils and preferably, triheptanoin and derivatives thereof.
Abstract: The present disclosure relates to specific (poly-)glycerol partial esters with at least one carboxylic acid and one polyfunctional carboxylic acid, and to the use thereof as emulsifier and to formulations comprising partial esters of the present disclosure.
Type:
Application
Filed:
March 2, 2011
Publication date:
December 8, 2011
Applicant:
EVONIK GOLDSCHMIDT GMBH
Inventors:
Hans Henning Wenk, Juergen Meyer, Stefan Bergfried, Hannelore Foetsch
Abstract: Methods of making a liquid crystal mixture essentially comprised of at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one alkali reactant. The resultant mixture includes at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one salt of said fatty acid ester or fatty acid. The resultant mixture exhibits enhanced stability and aqueous solubility of fatty acids and fatty acid esters. When medium chain fatty acid monoglycerides are used in the method, the resultant mixture exhibits antimicrobial efficacy.
Type:
Application
Filed:
October 18, 2010
Publication date:
December 8, 2011
Applicant:
COPPERHEAD CHEMICAL COMPANY
Inventors:
Richard Peter Curtis Calvert, Charles D. Cappuccino, James David Mosbaugh, Edmund L. Phelan
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Abstract: The present invention relates to compounds of the formula (I) wherein X1 and X2 independently represent O, NH or S, R1 and R2 are independently selected from the group consisting of a C1-C30 hydrocarbyl group, an amino acid bonded via an amide bond or a peptide bonded via an amide bond each having up to 200 amino acids, the conjugated residue X1 or X2 in this case being NH, and hydrogen, both radicals R1 and R2 preferably not being H, wherein R3 is a residue selected from group consisting of —S—R6, wherein R6 is a C1-C30 hydrocarbyl group, at least one of R1 and R2 not being H when X1 and X2 are oxygen, —S—CH2—CH(NH2)(COOH) (cysteine-S-yl), a homologue or derivative (e.g.
Type:
Grant
Filed:
May 3, 2006
Date of Patent:
November 29, 2011
Assignee:
Biogen Idec International GmbH
Inventors:
Rajendra Kumar Joshi, Hans-Peter Strebel, Jitka Ulrichová, Thomas J. Schmidt
Abstract: Salts of L-carnitine and alkanoyl L-carnitines with phytic acid of general formula (I), and the process of preparing the same, wherein the mole ratio between the L-carnitine or its alkanoyl derivatives cation and phytic acid anion be within the range of 1:1 to 6:1, wherein: n=1-6; R1 is the phytate anion; R is either hydrogen, a straight alkanoyl group having 2-12 carbon atoms or a branched-chain alkanoyl group having 2-12 carbon atoms.
Abstract: The present invention relates to tautomycetin (TTN) and analogs thereof. Also provided are methods of using TTN and analogs thereof in the treatment of various diseases relating to SHP2 function.
Abstract: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered, carboxylic acid salt, a liquid block copolymer of ethylene oxide and propylene oxide, and a tocopherol.
Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.
Type:
Application
Filed:
February 11, 2011
Publication date:
October 6, 2011
Inventors:
Robert C. Axtell, Lawrence Steinman, May H. Han, Brigit A. de Jong, Chander Raman, Michael Walker, Jing Shi
Abstract: This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease.
Abstract: The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by administrating PKC agonist into an animal model. Therefore, the composition of the present invention comprising PKC agonist as an active ingredient can be effectively used for the prevention and treatment of absence seizure and for the production of health improving functional food.
Type:
Application
Filed:
August 5, 2010
Publication date:
October 6, 2011
Inventors:
Eunji Cheong, Hee-Sup Shin, Yihong Zheng, Kyoobin Lee, Jungryun Lee, Seongwook Kim, Maryam Sanati, Sukyung Lee, Yeon-Soo Kim
Abstract: Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB0,+ are provided. The short-chain fatty acid or derivative thereof can be attached to the amino acid through a hydroxyl group of the amino acid to form a fatty acid ester of the amino acid, or it can be attached through the amino group of the amino acid to form a fatty-acid amide of the amino acid. Serine butyrate (O-butyryl serine) is a preferred prodrug. These prodrugs are useful for treatment of colon cancer, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lung cancer, cervical cancer, and cancers resulting from metastases from primary colon cancer sites. Methods of delivering biologically-active short-chain fatty acids or derivatives thereof to cells in need of these molecules and methods of treating diseases using the prodrugs of this invention are also provided.
Type:
Application
Filed:
March 3, 2011
Publication date:
October 6, 2011
Applicant:
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC
Inventors:
VADIVEL GANAPATHY, PUTTER D. PRASAD, ROBERT G. MARTINDALE
Abstract: The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.
Abstract: The present invention provides an oil-in-water cosmetic excellent in emulsion stability. The oil-in-water cosmetic includes (a) oil-droplet particles consisting of an oil component to be emulsified; (b) vesicle particles for stabilizing the oil-droplet particles; and (c) an aqueous phase containing water and a monohydric aliphatic alcohol having 1 to 4 carbon atoms. It is preferred that the vesicle particles are formed with an amphiphilic substance which spontaneously forms vesicle particles, and that they are localized on surfaces of the oil-droplet particles. It is preferred that the amphiphilic substance be a polyoxyethylene hydrogenated castor oil derivative represented by the following formula (1), wherein E=L+M+N+X+Y+Z, and that said E which represents the average addition mole number of ethylene oxide is 10 to 20.
Abstract: The invention relates to compositions containing one or more compounds of the formula (1), wherein R1CO and R2CO are linear or branched saturated acyl groups independent of each other, having 18 to 24 C atoms, and A? is a counter-ion, and the total amount of C18-23-alkyl COO groups is 40.0 wt.-% or more, based on all groups R1COO— and R2COO—. The compositions are, for example, cosmetic, dermatological, or pharmaceutical compositions.
Type:
Application
Filed:
July 31, 2008
Publication date:
September 29, 2011
Applicant:
CLARIANT FINANCE (BVI) LIMITED
Inventors:
Matthias Loeffler, Franz-Xaver Scherl, Tom Fricke
Abstract: The present invention relates to compositions and methods for treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy comprising monocholine salt of succinic acid of a formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is dicholine salt of succinic acid of a formula (II).
Abstract: The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS).
Abstract: Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions.
Abstract: A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat hepatic and genetic disorders related to copper overload. Multiple other compounds may be added with the instant claimed compounds and may be delivered as a pharmaceutical dose suitable for treating Wilson's disease.
Abstract: Medicaments and therapeutic compositions contain (1) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, (2) glucosamine sulfate, and (3) undenatured Type II collagen. One source of the fatty acids or derivatives thereof is fish oil. The compositions are useful for promoting joint health in a subject.
Abstract: The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.
Abstract: A pharmaceutical composition comprises at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, such as orlistat, at least one surfactant, and at least one dispersant.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
September 6, 2011
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Passchier Christiaan de Smidt, Paul Hadvary, Hans Lengsfeld, Thomas Rades, Hans Steffen, Joseph Tardio
Abstract: The present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of carbon atoms, wherein the fatty acid group comprises a carbon chain having 5 to 15 carbon atoms.
Abstract: The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid triglyceride (DHA-TG) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration.
Type:
Application
Filed:
February 18, 2011
Publication date:
August 25, 2011
Applicant:
Martek Biosciences Corporation
Inventors:
Jung LEE, Bernard A. Mikrut, Xuejun Tang
Abstract: The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone bodies, reduces amyloid-? (A?) deposition in AD patients, thereby improving cognition and locomotive skills.
Abstract: Compositions and methods for the treatment of intestinal infections. Compositions that include a liquid crystal mixture of an antimicrobial glycerol fatty acid ester and a polyhydric alcohol inhibit the growth of numerous deleterious intestinal pathogenic bacteria, including C. difficile. C. difficile is the causative agent in an increasing number of antibiotic-resistant bacterial infections. The formulations may be administered orally as capsules or soft gels, or alternatively as a enema, colonic, or rectal suppository. When combined with a probiotic supplement, the liquid crystal combinations reported here are able to treat an intestinal bacterial infection effectively and safely, thus promoting general intestinal health.
Type:
Application
Filed:
February 4, 2011
Publication date:
August 18, 2011
Applicant:
COPPERHEAD CHEMICAL COMPANY, INC.
Inventors:
James David Mosbaugh, Richard Peter Curtis Calvert, Eric J. Brooks
Abstract: The present invention relates to a novel process for the preparation of ?-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid (1), which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2), and its analogues.
Abstract: Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 [“Lp-PLA2”] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 Score™ in humans, by administering an effective amount of eicosapentaecnoic acid [“EPA”], an omega-3 polyunsaturated fatty acid [“PUFA”].
Type:
Application
Filed:
January 10, 2011
Publication date:
July 21, 2011
Applicant:
E.I. DU PONT DE NEMOURS AND COMPANY
Inventors:
PETER JOHN GILLIES, Ernst John Schaefer
Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.